Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$45.38 USD

45.38
37,372,119

-1.84 (-3.90%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $45.50 +0.12 (0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (90 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks News

Zacks Equity Research

The Zacks Analyst Blog Highlights: DIS, NVO, BHP, AVGO and LLY

The Zacks Analyst Blog Highlights: DIS, NVO, BHP, AVGO and LLY

Sheraz Mian headshot

Top Research Reports for Disney, Novo Nordisk & BHP

Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Novo Nordisk (NVO) and BHP Group (BHP).

Zacks Equity Research

Lilly (LLY) Gets FDA Approval for Higher Doses of Trulicity

Lilly's (LLY) higher doses of Trulicity led to superior reductions in blood glucose level and weight in type II diabetes patients compared to the currently available dose.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approval for Roche's SMA Drug & Other Updates

Teaser: FDA approves Roche's (RHHBY) new SMA drug, Evrysdi (risdiplam).

Zacks Equity Research

Novo Nordisk (NVO) Resumes Phase III Hemophilia Studies

Novo Nordisk (NVO) resumes the phase III studies on concizumabin in hemophilia A and B patients regardless of inhibitor status.

Zacks Equity Research

Novo Nordisk's (NVO) Q2 Earnings Beat Estimates, Sales Miss

Novo Nordisk's (NVO) earnings surpass estimates but revenues miss the same in the second quarter of 2020.

Zacks Equity Research

Novo Nordisk's Shares Rise on New Approvals, Strong Portfolio

Shares of Novo Nordisk (NVO) rally on solid product portfolio aided by new approvals.

Sheraz Mian headshot

Top Stock Reports for Alphabet, Merck & Medtronic

Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Merck (MRK) and Medtronic (MDT).

Zacks Equity Research

Novo Nordisk Completes Two Studies on Obesity Candidate

Novo Nordisk (NVO) provides data from a monotherapy study and a combination study on AM833.

Zacks Equity Research

Merck's Steglatro Non-Inferior in Cardiovascular Outcomes Study

Merck's (MRK) type 2 diabetes drug, Steglatro, achieves primary endpoint of non-inferiority in major adverse CV events compared to placebo in a late-stage cardiovascular outcomes study.

Kinjel Shah headshot

Pharma Stock Roundup: Coronavirus Updates From ABBV, LLY, JNJ, FDA Approvals

J&J (JNJ), AbbVie (ABBV) and Lilly (LLY) make progress in coronavirus research efforts.

Sriparna Ghosal headshot

3 Diabetes Management Stocks in the Spotlight Amid Coronavirus

Amid the widespread pandemic crisis, the diabetes management sector continues to thrive on account of multiple positive developments

Zacks Equity Research

Novo Nordisk to Acquire Corvidia Therapeutics for $725M Cash

Novo Nordisk (NVO) enters into a deal to acquire Corvidia Therapeutics for an upfront payment of $725 million in cash.

Zacks Equity Research

Lilly Begins Cardiovascular Outcomes Study on Tirzepatide

Lilly (LLY) announces that the first patient dose has been delivered in a cardiovascular outcome study on its novel diabetes candidate, tirzepatide.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Honeywell International, Amgen and S&P Global

The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Honeywell International, Amgen and S&P Global

Sheraz Mian headshot

Top Stock Reports for Novo Nordisk, IBM & Honeywell

Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk (NVO), International Business Machines (IBM) and Honeywell International (HON).

Kinjel Shah headshot

Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY

Novo Nordisk (NVO) and Bristol-Myers (BMY) announce Q1 results. Pfizer (PFE), Roche (RHHBY) and Lilly (LLY) provide update on their coronavirus-related research efforts.

Zacks Equity Research

Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates

Novo Nordisk (NVO) beats on Q1 sales and earnings, and maintains outlook amid the coronavirus pandemic.

Zacks Equity Research

SNY vs. NVO: Which Stock Is the Better Value Option?

SNY vs. NVO: Which Stock Is the Better Value Option?

Zacks Equity Research

The Zacks Analyst Blog Highlights: Visa, Novo Nordisk, American Tower, Caterpillar and 3M

The Zacks Analyst Blog Highlights: Visa, Novo Nordisk, American Tower, Caterpillar and 3M

Zacks Equity Research

The Zacks Analyst Blog Highlights: Alibaba, Pfizer, S&P Global, Novo Nordisk and Duke Energy

The Zacks Analyst Blog Highlights: Alibaba, Pfizer, S&P Global, Novo Nordisk and Duke Energy

Mark Vickery headshot

Top Analyst Reports for Alibaba, Pfizer & S&P Global

Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), Pfizer (PFE) and S&P Global (SPGI).

Zacks Equity Research

Novo Nordisk's Rybelsus Gets EU Nod for Type II Diabetes

Novo Nordisk (NVO) gains the EU approval for Rybelsus to address adult patients with insufficiently-controlled type II diabetes for improving glycemic control as an adjunct to diet and exercise.

Zacks Equity Research

NVS vs. NVO: Which Stock Should Value Investors Buy Now?

NVS vs. NVO: Which Stock Is the Better Value Option?

Zacks Equity Research

The Zacks Analyst Blog Highlights: Alphabet, Procter & Gamble, Philip Morris, Novo Nordisk and Tesla

The Zacks Analyst Blog Highlights: Alphabet, Procter & Gamble, Philip Morris, Novo Nordisk and Tesla